Condor Gold {AIM:CNR} CEO Mark Child delighted shareholders by announcing the discovery of a new area of gold mineralisation at Real De La Cruz, la India, in mining friendly Nicaragua last week.
This discovery, if confirmed by drilling, would enable this deposit to become a low grade satellite feeder for the main mine operation at La India.
Scorpio Gold {TSX.V: SGN} announce lower production and revenue figures YOY.
Installation of the new carbon column will increase the processing of pregnant leach solution and as a result, lower leach pad inventory and increase production.
WesternZagros {TSX.V: WZR} announce they declined a $1.46 per share offer for the company!
WZR are raising $400 million to fund their work programs on the Garmian and Kurdamir blocks.
Continue reading
Scorpio Gold {TSX.V:SGN} continued their run of news releases to the market with a further drilling update from the Bluelite Deposit at Mineral Ridge, Nevada.
Of particular note are the shallow depths that these grades were located at, starting at 12 meters.
Inovio {NYSE: INO} reported their Second Quarter Financial Results.
Revenue and expenses were both higher due to the Roche partnership and costs incurred in preparation for future clinical trials.
Cash on hand is $109 million, sufficient for working capital requirements until 2017.
Scorpio Gold Corp. {TSX.V: SGN} made their second significant announcement in ten days, as they continue to improve an already impressive production story, in a first class jurisdiction.
Following on from their extended LOM news release on the 21st July, SGN have reported further drilling results from their Brodie Satellite Deposit at Mineral Ridge, Nevada. Some significant intercepts were returned.
Terrace Energy Corp.{TSX.V:TZR} pleased the market with an over allotment of some $3 million adding to the recent $20 million raised and announced on July 23rd, for a grand total of 10,820,000 shares raising $23,019,550.
Nymox {NASDAQ: NYMX} announces positive efficacy results in their phase 3 trial of NX-1207 for BPH.
Evaluation of data from the study confirmed that the NX-1207 reinjection treatment had been well tolerated by patients, who had not displayed any drug related significant side effects, not impaired sexual function.
Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses
Avalon Rare Metals Inc. {TXS.v: AVL} closed their recently announced financing in short order, with the private placement segment healthly over-subscribed.
Avalon raised CAD $2.166 million with a combination of a private placement and flow through shares.
